Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 2/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17545287 | 0.91 | ACLY (0.54) | ACLYP2RY4ACHEXIAPBIRC2 | |
| SCHEMBL19219757 | 0.88 | CYP11B2 (0.41) | P2RY4ACHEHTR2AHTR2CEDNRA | |
| SCHEMBL19219772 | 0.86 | ACLY (0.51) | ACLYP2RY4XIAPBIRC2TRIM24 | |
| SCHEMBL19219770 | 0.83 | ACLY (0.49) | ACLYP2RY4XIAPBIRC2HTR2A | |
| SCHEMBL19219768 | 0.80 | ACLY (0.44) | ACLYP2RY4XIAPBIRC2 | |
| SCHEMBL17545073 | 0.79 | CYP11B2 (0.52) | ACLYACHEHTR2AHTR2CCYP11B2 | |
| SCHEMBL19219762 | 0.78 | ACLY (0.57) | ACLYP2RY4XIAPBIRC2TRIM24 | |
| SCHEMBL17545354 | 0.77 | ACLY (0.61) | ACLYP2RY4TRIM24NPC1LMNA | |
| SCHEMBL19219758 | 0.74 | KDM4E (0.46) | ACLYHTR2AHTR2CTRIM24LMNA | |
| SCHEMBL17545337 | 0.74 | ACLY (0.60) | ACLYP2RY4XIAPBIRC2TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | INMT, MGAM, NNMT | ACLY 1668/4885P2RY4 4620/4885ACHE 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.